CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Synlogic, Inc.
(Nasdaq: SYBX), a clinical stage company bringing the
transformative potential of synthetic biology to medicine, today
announced the Company will release its third quarter 2020 financial
results before the market opens on Thursday,
November 5, 2020. The press release will be followed by a
conference call at 8:30 am ET, which
will be open to the public via telephone and webcast. During the
conference call, the Company will review its financial results and
provide a corporate update.
The conference call dial-in numbers are (844) 815-2882 for
domestic callers and (213) 660-0926 for international callers. The
conference ID number for the call is 8557525. Participants may
access the live webcast via a link on
the Synlogic website in the Events Calendar of
the Investors and Media section. For those unable to participate in
the conference call or webcast, a replay will be available for 30
days on the Company's website.
About Synlogic
Synlogic™ is bringing the
transformative potential of synthetic biology to medicine. With a
premiere synthetic biology platform that leverages a reproducible,
modular approach to microbial engineering, Synlogic designs
Synthetic Biotic therapeutics that target validated underlying
biology to treat disease in new ways. Synlogic's proprietary
pipeline includes Synthetic Biotics for the treatment of metabolic
disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria
(HOX). The company is also building a portfolio of partner-able
assets in immunology and oncology.
Forward-Looking Statements
This press release contains
"forward-looking statements" that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release regarding strategy, future operations, clinical development
plans, future financial position, future revenue, projected
expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this
press release, the words "may," "could," "should," "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "predict" and
similar expressions and their variants, as they relate to Synlogic
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic's platform to
develop therapeutics to address a wide range of diseases including:
cancer, inborn errors of metabolism, and inflammatory and
immune disorders; the future clinical development of Synthetic
Biotic medicines; the approach Synlogic is taking to discover and
develop novel therapeutics using synthetic biology; the expected
timing of Synlogic's clinical trials and availability of clinical
trial data; the timing and progress of our Phase 1 clinical trial
of SYNB1891 in patients with advanced solid tumors or lymphoma; and
the potential benefits of SYNB1891. Actual results could differ
materially from those contained in any forward-looking statement as
a result of various factors, including: the uncertainties inherent
in the clinical and preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the SEC. The
forward-looking statements contained in this press release
reflect Synlogic's current views with respect to future
events. Synlogic anticipates that subsequent events and
developments will cause its views to change. However, while
Synlogic may elect to update these forward-looking statements in
the future, Synlogic specifically disclaims any
obligation to do so. These forward-looking statements should not be
relied upon as representing Synlogic's view as of any date
subsequent to the date hereof.
View original
content:http://www.prnewswire.com/news-releases/synlogic-announces-third-quarter-2020-conference-call--webcast-301160250.html
SOURCE Synlogic, Inc.